Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES-X-ray)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03928184
Recruitment Status : Recruiting
First Posted : April 26, 2019
Last Update Posted : November 13, 2019
Sponsor:
Information provided by (Responsible Party):
Samumed LLC

Brief Summary:
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize radiographs and patient reported outcomes (PROs) to evaluate the safety and efficacy of lorecivivint.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Drug: Lorecivivint Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 725 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Actual Study Start Date : May 17, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 0.07 mg lorecivivint
One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
Drug: Lorecivivint
Healthcare professional-administered intra-articular injection; performed on Day 1
Other Name: SM04690

Placebo Comparator: Vehicle
One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
Drug: Placebo
Healthcare professional-administered intra-articular injection; performed on Day 1




Primary Outcome Measures :
  1. Change from baseline in OA pain in the target knee (pain NRS) [ Time Frame: Baseline and Week 12 ]
    Evaluate change from baseline OA pain in the target knee as assessed by the weekly averages of daily pain numeric rating scale (NRS). The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain.


Secondary Outcome Measures :
  1. Change from baseline in OA pain in the target knee (Pain NRS) [ Time Frame: Baseline, Weeks 24 and 52 ]
    Evaluate change from baseline OA pain in the target knee as assessed by the weekly averages of daily pain Numeric Rating Scale (NRS). The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain.

  2. Change from baseline in OA function in the target knee (WOMAC Function) [ Time Frame: Baseline, Weeks 12, 24 and 52 ]
    Evaluate change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) physical function subscore (WOMAC Function). The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 68.

  3. Change from baseline in OA disease activity (Patient Global Assessment) [ Time Frame: Baseline, Weeks 12, 24 and 52 ]
    Evaluate change from baseline OA disease activity as assessed by Patient Global Assessment. The Patient Global Assessment is an 11-point [0-10] Numeric Rating Scale [NRS] on which the subjects will rate how they feel their target knee OA is doing, considering all the ways in which their target knee OA may affect them. The NRS is anchored by descriptors at each end ("Very Good" on the left and "Very Bad" on the right).

  4. Change from baseline in usage of nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for target knee OA pain [ Time Frame: Baseline and Week 52 ]

Other Outcome Measures:
  1. Change from baseline in serum bone biomarkers [ Time Frame: Baseline and Week 56 ]
    Evaluate change from baseline in serum bone biomarkers N-terminal propeptides of procollagen type I [PINP] and β-C-terminal telopeptide [β-CTX]

  2. Change from baseline in a serum cartilage biomarker [ Time Frame: Baseline and Week 56 ]
    Evaluate change from baseline in serum cartilage biomarker cartilage oligomeric matrix protein [COMP]

  3. Change from baseline in medial joint space width (mJSW) in the target knee [ Time Frame: Baseline and Week 52 ]
    Evaluate change from baseline in mJSW as documented by radiograph of the target knee

  4. Change from baseline in health-related quality of life (HRQOL) [ Time Frame: Baseline and Week 52 ]
    Evaluate change from baseline in HRQOL as assessed by the 36-Item Short Form Health Survey (SF-36). The SF-36 consists of eight scaled scores which are the weighted sums of the questions in their section (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health). Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

  5. Change from baseline in OA pain in the target knee (WOMAC Pain) [ Time Frame: Baseline, Weeks 12, 24 and 52 ]
    Evaluate change from baseline in OA pain in the target knee as assessed by WOMAC pain subscore (WOMAC Pain). The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore ranges from 0 to 20.

  6. Change from baseline in OA pain, function and stiffness (WOMAC Total score) [ Time Frame: Baseline, Weeks 12, 24 and 52 ]
    Evaluate change from baseline in OA pain, function and stiffness as a composite outcome measure as assessed by WOMAC Total score. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/highest stiffness/lowest function). WOMAC Total is a composite of the three domains (pain/stiffness/function) with a total score of 0 to 96.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females between 40 and 80 years of age, inclusive, in general good health apart from their knee OA
  2. Ambulatory (single assistive devices such as canes allowed if needed less than 50% of the time, subjects requiring a walker are excluded)
  3. Diagnosis of femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria at Screening Visit 1 (clinical AND radiographic criteria); OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis)
  4. mJSW by radiograph between 1.5 and 4 mm, inclusive, in the target knee at Screening Visit 1 as assessed by independent central readers
  5. Radiographic disease Stage 2 or 3 in the target knee at Screening Visit 1 according to the Kellgren-Lawrence (KL) grading of knee OA as assessed by independent central readers
  6. Pain compatible with OA of the knee(s) for at least 26 weeks prior to Screening Visit 1
  7. Primary source of pain throughout the body is due to OA in the target knee
  8. Body mass index (BMI) ≤ 40 kg/m2
  9. Widespread Pain Index (WPI) score of ≤ 4 and a Symptom Severity Question 2 (SSQ2) score of ≤ 2 at Screening Visit 1 and Day 1
  10. Pain NRS scores recorded for the target knee on at least 4 out of the 7 days immediately preceding Day 1
  11. Pain NRS scores recorded for the non-target knee on at least 4 out of the 7 days immediately preceding Day 1
  12. Daily OA knee pain diary average NRS intensity score ≥ 4 and ≤ 8 in the target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1
  13. Daily OA knee pain diary average NRS intensity score < 4 in the non-target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1
  14. WOMAC Pain score of 20-40 (out of 50) for the target knee at baseline regardless of if the subject is on symptomatic oral treatment (baseline questionnaire completed during the screening period prior to randomization)
  15. WOMAC Function score of 68-136 (out of 170) for the target knee at baseline regardless of if the subject is on symptomatic oral treatment (baseline questionnaire completed during the screening period prior to randomization)
  16. Willingness to use an electronic diary daily in the evening for the screening period and 56-Week study duration
  17. Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, benzodiazepine, methaqualone, and tricyclic antidepressants, unless any of these drugs are allowed per protocol and prescribed by a physician to treat a specific condition
  18. Subjects with depression or anxiety must be clinically stable for 12 weeks prior to Screening Visit 1 and, if on treatment for depression or anxiety, be on 12 weeks of stable therapy
  19. Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
  20. Subjects must have read and understood the informed consent form (ICF), and must have signed and dated it prior to any study-related procedure being performed

Exclusion Criteria:

  1. Women who are pregnant, lactating, or have a positive or indeterminate pregnancy result at Screening Visit 2 or Day 1
  2. Women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy, but NOT tubal ligation), who are sexually active, and who are not willing to use birth control during the study period
  3. Men who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized or who are not using birth control
  4. Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the target knee (varus > 10°, valgus > 10°) by radiograph as assessed by independent central readers
  5. Partial or complete joint replacement in either knee
  6. Currently requires use of a lower extremity prosthesis, and/or a structural knee brace (i.e., a knee brace that contains hardware)
  7. Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Screening Visit 1
  8. Any intra-articular (IA) injection into the target knee with a therapeutic aim including, but not limited to, viscosupplementation (e.g., hyaluronic acid), platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Screening Visit 1; treatment of the target knee with IA glucocorticoids more than 12 weeks prior to Screening Visit 1 is allowed
  9. Effusion of the target knee clinically requiring aspiration within 12 weeks prior to Screening Visit 1
  10. Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to Screening Visit 1
  11. Any bone fracture(s) within 26 weeks prior to Screening Visit 1
  12. Previous treatment with SM04690
  13. Subjects who have previously failed screening on this protocol and fail to meet re-screening criteria
  14. Participation in a clinical research trial that included the receipt of an investigational product (IP) or any experimental therapeutic procedure for knee OA within 26 weeks prior to Screening Visit 1, or planned participation in any such trial
  15. Treatment with systemic (oral, intramuscular, or intravenous) glucocorticoids greater than 10 mg prednisone or the equivalent per day within 4 weeks prior to Screening Visit 1
  16. Current use, or use within 12 weeks prior to Screening Visit 1, of centrally acting analgesics
  17. Current use, or use within 12 weeks prior to Screening Visit 1, of anticonvulsants
  18. Subjects requiring the use of opioids > 1x per week within 12 weeks prior to Screening Visit 1
  19. Topical local anesthetic agents (gels, creams, or patches such as the Lidoderm patch) used for the treatment of knee OA within 7 days of Screening Visit 1
  20. Any surgery scheduled during the study period. Non-surgical invasive procedures conducted for a diagnostic or therapeutic purpose scheduled during the study period are allowed
  21. History of malignancy within the last 5 years; however, subjects with prior history of in situ basal or squamous cell skin cancer are eligible if completely excised. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to Screening Visit 1.
  22. Clinically significant abnormal screening hematology values, blood chemistry values, or urinalysis values as determined by the Investigator
  23. Any condition, including laboratory findings not included in the Screening Visit 2 laboratory tests and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  24. Other conditions that, in the opinion of the Investigator, could affect study endpoint assessments of either knee, including, but not limited to, peripheral neuropathy (e.g., diabetic neuropathy), symptomatic hip osteoarthritis, symptomatic degenerative disc disease, and patellofemoral syndrome
  25. Comorbid conditions that could affect study endpoint assessments of the target knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia
  26. History of mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder
  27. Any known active infections, including urinary tract infection, upper respiratory tract infection, sinusitis, suspicion of IA infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV) at Day 1
  28. Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy in the opinion of the Investigator. In addition, subjects with an HbA1c > 9 at Screening Visit 2 will be excluded.
  29. If using NSAIDs and/or acetaminophen, subjects who have not maintained a stable regimen in the opinion of the Investigator for at least 4 weeks prior to Screening Visit 1
  30. Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment
  31. Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at any investigative site, or are directly affiliated with the study at any investigative site
  32. Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study, or who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of said employees responsible for the conduct of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928184


Contacts
Layout table for location contacts
Contact: Samumed Clinical Trials 1-855-222-0515 clinicaltrials@samumed.com

  Show 91 Study Locations
Sponsors and Collaborators
Samumed LLC
Investigators
Layout table for investigator information
Study Director: Yusuf Yazici, M.D. Samumed LLC

Layout table for additonal information
Responsible Party: Samumed LLC
ClinicalTrials.gov Identifier: NCT03928184     History of Changes
Other Study ID Numbers: SM04690-OA-11
First Posted: April 26, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Samumed LLC:
SM04690
Wnt pathway inhibitor
osteoarthritis
Samumed
lorecivivint
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Adavivint
Anti-Inflammatory Agents